Search results for " effect"

showing 10 items of 7524 documents

The Therapeutic Effects of Whole-Body Vibration in Patients With Fibromyalgia. A Randomized Controlled Trial

2021

Fibromyalgia is a chronic pain disease with few effective therapeutic options. We evaluated the efficacy of a 12-weeks therapy program that involves the use of whole body vibration in patients with fibromyalgia. The experimental group (N = 20 patients) participated in a neuromuscular training with a rotational whole body vibration platform for 12 weeks. The control group (N = 20 patients) received no physiotherapy treatment. The following variables were assessed before, after and 3 months after the therapy program: Fibromyalgia impact questionnaire, pain intensity, quality of life, sensitivity measurements (pressure pain thresholds, vibration thresholds), motor function tasks (Berg scale, 6…

medicine.medical_specialtyIsometric exerciselaw.invention03 medical and health sciences0302 clinical medicineQuality of lifeRandomized controlled triallawFibromyalgiamedicineWhole body vibrationRC346-429Original ResearchBalance (ability)030203 arthritis & rheumatologybusiness.industryTherapeutic effectChronic painbalancewhole-body vibrationmedicine.diseaseNeurologymotor performancePhysical therapyfibromyalgiapain sensitivityNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

Potentially Detrimental Effects of Hyperosmolality in Patients Treated for Traumatic Brain Injury

2021

Hyperosmotic therapy is commonly used to treat intracranial hypertension in traumatic brain injury patients. Unfortunately, hyperosmolality also affects other organs. An increase in plasma osmolality may impair kidney, cardiac, and immune function, and increase blood–brain barrier permeability. These effects are related not only to the type of hyperosmotic agents, but also to the level of hyperosmolality. The commonly recommended osmolality of 320 mOsm/kg H2O seems to be the maximum level, although an increase in plasma osmolality above 310 mOsm/kg H2O may already induce cardiac and immune system disorders. The present review focuses on the adverse effects of hyperosmolality on the function…

medicine.medical_specialtyKidneyOsmotic concentrationTraumatic brain injurybusiness.industryosmolar gapmannitolRGeneral MedicineReviewmedicine.diseaseHypertonic salinePlasma osmolalitymedicine.anatomical_structureEndocrinologyImmune systemInternal medicineRenal physiologymedicineMedicineAdverse effectbusinessosmolalitytraumatic brain injury (TBI)hypertonic salineJournal of Clinical Medicine
researchProduct

Mathematical simulation of Doppler changes in late-onset smallness; progression patterns of cerebral and umbilical anomalies define two types of late…

2019

To evaluate the progression of Doppler abnormalities in fetuses with late-onset fetal smallness (SGA) that become growth restricted (FGR).524 Doppler examinations of the umbilical and cerebral arteries systems, belonging to 442 late-onset SGA fetuses after week 34, were studied, evaluating by means of the statistical difference with the respective abnormal centiles, the pattern of progression into abnormal Doppler values and the distribution and cumulative sum of Doppler anomalies according to the interval to delivery.Only one third (33.5%,Two thirds of late-onset fetal smallness occurs without hemodynamic changes. In half of the remaining cases an initial cerebral vasodilation defines a gr…

medicine.medical_specialtyLate onset030204 cardiovascular system & hematologyUltrasonography PrenatalUmbilical Arteries03 medical and health sciencessymbols.namesake0302 clinical medicineFetusPregnancyInternal medicinemedicineFetal growthHumansreproductive and urinary physiologyFetus030219 obstetrics & reproductive medicineFetal Growth Retardationbusiness.industryHemodynamicsInfant NewbornObstetrics and GynecologyUltrasonography Dopplermedicine.diseaseembryonic structuresPediatrics Perinatology and Child HealthInfant Small for Gestational Agecardiovascular systemsymbolsCardiologySmall for gestational ageFemalebusinessDoppler effectcirculatory and respiratory physiologyMathematical simulationThe journal of maternal-fetalneonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
researchProduct

Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review

2021

Anabolic-androgenic steroids (AASs) are a large group of molecules including endogenously produced androgens, such as testosterone, as well as synthetically manufactured derivatives. AAS use is widespread due to their ability to improve muscle growth for aesthetic purposes and athletes’ performance, minimizing androgenic effects. AAS use is very popular and 1–3% of US inhabitants have been estimated to be AAS users. However, AASs have side effects, involving all organs, tissues and body functions, especially long-term toxicity involving the cardiovascular system and the reproductive system, thereby, their abuse is considered a public health issue. The aim of the proposed review is to highli…

medicine.medical_specialtyLeadership and Managementinjuryorgan damagelcsh:MedicineHealth InformaticsInjuryReviewanabolic androgenic steroidsBioinformaticschronic administration03 medical and health sciences0302 clinical medicineHealth Information ManagementmedicineAASstoxicity.Adverse effect030304 developmental biology0303 health sciencesbiologyToxicitybusiness.industryAthletesHealth PolicyPublic healthlcsh:RtoxicityTestosterone (patch)Organ damageAnabolic-Androgenic Steroidsbiology.organism_classificationAASChronic administrationEducational interventionsWhole bodybusinessLarge groupAnabolic androgenic steroid030217 neurology & neurosurgeryanabolic androgenic steroidHealthcare
researchProduct

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

2020

Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to daratumumab monotherapy and collected safety and patient-reported outcomes data for patients with relapsed or refractory multiple myeloma. At 15 centers across Spain, intravenous daratumumab (16 mg/kg) was administered to 73 patients who had >= 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who were double refractory to both. The median duration of daratumumab treatment was 3.3 (range: 0.03-13.17)…

medicine.medical_specialtyLeukopenialcsh:RC633-647.5business.industryAnemiaDaratumumablcsh:Diseases of the blood and blood-forming organsHematologyNeutropeniamedicine.disease002ArticleClinical trialRefractoryInternal medicineProteasome inhibitormedicinemedicine.symptombusinessAdverse effectmedicine.drugHemaSphere
researchProduct

Multifocal disseminated lipoatrophy secondary to intravenous corticosteroid administration in a patient with adrenal insufficiency.

2002

Multifocal disseminated lesions of circumscribed lipoatrophy have not been described as an adverse reaction of intravenously applied drugs. A unique patient with adrenal insufficiency is reported who received corticosteroids intravenously and then had multiple lesions develop that were similar to focal lipoatrophy as known to occur secondary to faulty intradermal injections of corticosteroids.

medicine.medical_specialtyLipodystrophymedicine.drug_classbusiness.industryPrednisoloneDermatologyMiddle Agedmedicine.diseaseRisk AssessmentSeverity of Illness IndexSurgeryToxicitymedicineAdrenal insufficiencyCorticosteroidHumansFemalebusinessAdverse effectInfusions IntravenousLipoatrophyAdrenal InsufficiencyFollow-Up StudiesJournal of the American Academy of Dermatology
researchProduct

Positive Airway Pressure Treatment Reduces Glycated Hemoglobin (HbA1c) Levels in Obstructive Sleep Apnea Patients: Longitudinal Data from the Esada

2019

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN

medicine.medical_specialtyLongitudinal dataGastroenterologyComorbidities03 medical and health sciencesHba1c levelchemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinePositive airway pressuremedicine030212 general & internal medicinebusiness.industryType 2 Diabetes MellitusSleep apneaSystemic effectmedicine.diseaserespiratory tract diseasesObstructive sleep apnea030228 respiratory systemApnea–hypopnea indexchemistryCardiologyGlycated hemoglobinbusinessBody mass indexTurkish Thoracic Journal
researchProduct

Low-protein vegetarian diet does not have a short-term effect on blood acid–base status but raises oxygen consumption during submaximal cycling

2012

Abstract Background Acid–base balance refers to the equilibrium between acids and bases in the human body. Nutrition may affect acid–base balance and further physical performance. With the help of PRAL (potential renal acid load), a low-protein vegetarian diet (LPVD) was designed to enhance the production of bases in body. The aim of this study was to investigate if LPVD has an effect on blood acid–base status and performance during submaximal and maximal aerobic cycling. Methods Nine healthy, recreationally active men (age 23.5 ± 3.4 yr) participated in the study and were randomly divided into two groups in a cross-over study design. Group 1 followed LPVD for 4 days and group 2 ate normall…

medicine.medical_specialtyLow proteinAcid–base balancechemistry.chemical_elementlcsh:TX341-641Clinical nutritionAcid–base homeostasisOxygenMedicineTerm effectFood sciencelcsh:Sports medicineNutritionNutrition and Dieteticsbusiness.industryAerobic performanceAcid loadchemistryPhysical therapyAcid–base reactionlcsh:RC1200-1245businessCyclinglcsh:Nutrition. Foods and food supplyFood ScienceResearch ArticleJournal of the International Society of Sports Nutrition
researchProduct

Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofraction…

2020

Objectives: To investigatewhether assessmentwith two geriatric screening tools shows a correlationwith clinical outcomes of patients aged 65 years or more, with early-stage Non-Small Cell Lung Cancer (es-NSCLC) treated with hypofractionated stereotactic radiotherapy. Methods: FromMarch 2014 to June 2018we retrospectively evaluated 42 patientswith stage I and II lung tumors. Patients were assessed with Charlson Comorbidity Index (CCI) and G8 screening tool. Median age was 74 years (range, 65–91). Stereotactic radiotherapy was performed with Helical Tomotherapy delivering 50–70 Gray (Gy) in 8–10 fractions. Toxicity was evaluated using Common Terminology Criteria for Adverse Events v4.0 criter…

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentRadiosurgeryChest painTomotherapySettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungmedicineHumansProspective Studies030212 general & internal medicineStage (cooking)Adverse effectProspective cohort studyLung cancerEarly Detection of CancerAgedRetrospective StudiesLung cancer Radiation therapy G8 Charlson comorbidity indexbusiness.industryCommon Terminology Criteria for Adverse EventsPrognosismedicine.diseaseTreatment OutcomeOncology030220 oncology & carcinogenesisCohortDose Fractionation RadiationRadiologyGeriatrics and Gerontologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessJournal of Geriatric Oncology
researchProduct

Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-contro…

2020

AbstractBACKGROUNDTreatment of severe Corona Virus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.METHODSIn this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage. They were randomly assigned to receive either UC-MSCs (4 × 107 cells per infusion) or placebo on day 0, 3, and 6. The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28. Other imaging outcomes, 6-minute walk test, maximum vital capaci…

medicine.medical_specialtyLungbusiness.industryIncidence (epidemiology)PlaceboGastroenterologyUmbilical cordmedicine.anatomical_structureInternal medicineDiffusing capacityClinical endpointmedicineStem cellAdverse effectbusiness
researchProduct